3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase 3
5
Phase 1/2
3
Phase 2/3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
6
Fallopian Tube Neoplasms
5
Lung Neoplasms
4
Stomach Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Inflammatory Breast Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Ductal, Breast
2
Adenocarcinoma Of Esophagus
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
The Neoadjuvant Therapy
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Seminoma
1
Recurrence
1
Primary Malignant Neoplasm of Ovary
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Interventions
Paclitaxel
2
Taxes
1
Neoadjuvant Therapy
1
Letrozole
1
Lapatinib
1
Gonadotropin-Releasing Hormone
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
Capecitabine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Inflammatory Breast Neoplasms
×
Paclitaxel
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled
NCT01426880
2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3
Completed
595 enrolled